Literature DB >> 7593704

An approach to efficacy screening of mouthrinses: studies on a group of French products (II). Inhibition of salivary bacteria and plaque in vivo.

P R Harper1, S Milsom, W Wade, M Addy, J Moran, R G Newcombe.   

Abstract

The aim of this study was to determine the value of screening studies to assess the efficacy of antiseptic mouthrinse products relative to proven products. The products tested were 6 antiseptic mouthrinses available in France. 4 contained chlorhexidine (Eludril, Hibident, Parodex and Prexidine) with Hibident considered the positive control. 1 product contained cetylpyridinium chloride (Alodont) and 1 hexetidine (Hextril). Saline was used as the negative control. The 1st study assessed the persistence of action of the products by recording salivary bacterial counts before and up to 7 h after single rinses. The 2nd study measured the inhibition of plaque regrowth, from a zero baseline, in the absence of tooth-brushing over a 4-day period. Both studies used blind randomised crossover designs balanced for residual effects. Salivary bacterial count reductions with time were highly significantly greater for Parodex to 5 h and Hibident and Prexidine to 7 h; There were no significant differences between the latter three chlorhexidine rinses except at 3 h, when decrements were significantly less with Parodex. Despite a mean trend in favour, Alodont, Eludril and Hextril were not significantly different from saline. Plaque inhibition by area and index was highly significantly different between products. Hibident, Parodex and Prexidine showed similar plaque inhibition and were significantly more effective than all other rinses. Eludril and Hextril were significantly more effective than saline but Alodont was not. Taken with the associated study in vitro and published reports on the same or similar products, it is apparent that efficacy of a product cannot be assumed merely because it contains a known active plaque inhibitor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593704     DOI: 10.1111/j.1600-051x.1995.tb00833.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  6 in total

1.  Multiple exposures to chlorhexidine and xylitol: adhesion and biofilm formation by Streptococcus mutans.

Authors:  Adriana Modesto; David R Drake
Journal:  Curr Microbiol       Date:  2006-04-25       Impact factor: 2.188

2.  Inhibition of de novo plaque growth by a new 0.03 % chlorhexidine mouth rinse formulation applying a non-brushing model: a randomized, double blind clinical trial.

Authors:  Carolina Mor-Reinoso; Andres Pascual; Jose Nart; Marc Quirynen
Journal:  Clin Oral Investig       Date:  2015-10-17       Impact factor: 3.573

3.  Susceptibilities of Candida albicans mouth isolates to antifungal agents, essentials oils and mouth rinses.

Authors:  Sara Carvalhinho; Ana Margarida Costa; Ana Cláudia Coelho; Eugénio Martins; Ana Sampaio
Journal:  Mycopathologia       Date:  2012-01-14       Impact factor: 2.574

4.  In vivo substantivity of 0.12% and 0.2% chlorhexidine mouthrinses on salivary bacteria.

Authors:  Maria Consuelo Cousido; Inmaculada Tomás Carmona; Lucia García-Caballero; Jacobo Limeres; Maximiliano Alvarez; Pedro Diz
Journal:  Clin Oral Investig       Date:  2009-08-08       Impact factor: 3.573

5.  Comparing the effect of 0.06% -, 0.12% and 0.2% Chlorhexidine on plaque, bleeding and side effects in an experimental gingivitis model: a parallel group, double masked randomized clinical trial.

Authors:  Maliha Haydari; Ayse Gul Bardakci; Odd Carsten Koldsland; Anne Merete Aass; Leiv Sandvik; Hans R Preus
Journal:  BMC Oral Health       Date:  2017-08-18       Impact factor: 2.757

Review 6.  An umbrella review of systematic reviews of the evidence of a causal relationship between periodontal microbes and respiratory diseases: Position paper from the Canadian Dental Hygienists Association.

Authors:  Salme E Lavigne; Jane L Forrest
Journal:  Can J Dent Hyg       Date:  2020-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.